Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2).

Journal of medicinal chemistry - 22 Feb 2024

Chen Zhen, Chen Jiahui, Mori Wakana, Yi Yongjia, Rong Jian, Li Yinlong, Leon Erick R Calderon, Shao Tuo, Song Zhendong, Yamasaki Tomoteru, Ishii Hideki, Zhang Yiding, Kokufuta Tomomi, Hu Kuan, Xie Lin, Josephson Lee, Van Richard, Shao Yihan, Factor Stewart, Zhang Ming-Rong, Liang Steven H

Abstract excerpt

Parkinson's disease (PD) is one of the most highly debilitating neurodegenerative disorders, which affects millions of people worldwide, and leucine-rich repeat kinase 2 (LRRK2) mutations have been involved in the pathogenesis of PD. Developing a potent LRRK2 positron emission tomography (PET) tracer would allow for in vivo visualization of LRRK2 distribution and expression in PD patients. In this work, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leucine
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Morpholines

Share to Nitriles

Share to Parkinson Disease

Share to Positron-Emission Tomography

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 38305157
DOI: 10.1021/acs.jmedchem.3c01687
PMCID: PMC10895652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2).PMID 38305157Read ↗

Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.Semantic proximity Read ↗

Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule InhibitorsSemantic proximity Read ↗

Positron emission tomography imaging of the P2X7 receptor with a novel tracer, [18F]GSK1482160, in a transgenic mouse model of Alzheimer's disease and healthy non‐human primatesSemantic proximity Read ↗

Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.Semantic proximity Read ↗

A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.Semantic proximity Read ↗

DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson's disease.Semantic proximity Read ↗

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.Semantic proximity Read ↗

Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.Semantic proximity Read ↗

Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule InhibitorsSemantic proximity Read ↗

Positron Emission Tomography (PET) Imaging Tracers for Serotonin ReceptorsSemantic proximity Read ↗

Exploration of Bicyclic Peptide Ligands for Immune-Specific PET Imaging: Targeting Tumor PD-L1 with [18F]AlF-BCY10959Semantic proximity Read ↗

Molecular tracers for the PET and SPECT imaging of diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.